Update on metabolic issues in HIV patients
Authors:
- Esteban MartinezEMEsteban Martinez
- 1 July 2014
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in HIV and AIDS
- Vol. 9 (4) , 332-339
Abstract
To report on the recent advances on lipids, diabetes, and body fat in HIV-infected patients from the perspective of aging. HIV infection causes microbial translocation and inflammation that contribute to hypertriglyceridemia and insulin resistance, and quantitative and qualitative HDL-cholesterol changes that further contributes to atherosclerosis. These changes are incompletely reversed by antiretroviral therapy. Protease inhibitors have the worse lipid profile among the currently used antiretroviral drugs. Etravirine, maraviroc, and raltegravir have a lipid impact better than other antiretroviral classes. The importance of genetic background on dyslipidemia of HIV-infected patients is becoming increasingly known. Lipodystrophy is associated with inflammation, dyslipidemia, diabetes, hypertension, and functional decline. Lipohypertrophy is becoming more common in HIV-infected patients influenced by the current obesity epidemics in the general population. Inflammation, cholesterol abnormalities, and lipodystrophy caused by both HIV infection and antiretroviral therapy may pose aging HIV-infected patients at a higher risk of comorbidities and frailty despite sustained viral suppression. Healthier lifestyles and strategies specifically addressed to diminish the impact of these pathophysiologic abnormalities will be needed for preserving the overall health in aging HIV-infected persons.Keywords
This publication has 61 references indexed in Scilit:
- Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapyNutrition Journal, 2013
- Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip studyBMC Infectious Diseases, 2013
- Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitorsBMC Infectious Diseases, 2013
- Relationship of ethnicity and CD4 Count with glucose metabolism among HIV patients on Highly-Active Antiretroviral Therapy (HAART)BMC Endocrine Disorders, 2013
- Recombinant Human Growth Hormone and Rosiglitazone for Abdominal Fat Accumulation in HIV-Infected Patients with Insulin Resistance: A Randomized, Double-Blind, Placebo-Controlled, Factorial TrialPLOS ONE, 2013
- Cardiometabolic risk factors among HIV patients on antiretroviral therapyLipids in Health and Disease, 2013
- A Pilot Study of Telmisartan for Visceral Adiposity in HIV Infection: The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) TrialPLOS ONE, 2013
- Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adultsLipids in Health and Disease, 2013
- Lipodystrophy defined by Fat Mass Ratio in HIV-infected patients is associated with a high prevalence of glucose disturbances and insulin resistanceBMC Infectious Diseases, 2012
- Increasing Rates of Obesity among HIV-Infected Persons during the HIV EpidemicPLOS ONE, 2010